CTLA4 and melanoma: CTLA4, a negative regulator of T-cell activation, was approved as the first immune checkpoint in melanoma treatment and anti-CTLA4 immunotherapy has shown outstanding antitumor efficacy in clinical trials of ovarian cancer patients (63).